FOLD Amicus Therapeutics Inc

Price (delayed)

$12.28

Market cap

$3.2B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.15

Enterprise value

$3.43B

Sector: Healthcare
Industry: Biotechnology

Highlights

Amicus Therapeutics's gross profit has surged by 55% YoY and by 8% QoQ
FOLD's revenue has surged by 54% year-on-year and by 8% since the previous quarter
Amicus Therapeutics's quick ratio has soared by 52% from the previous quarter but it has decreased by 16% YoY
FOLD's debt has surged by 118% since the previous quarter and by 115% year-on-year
The equity has contracted by 42% YoY and by 11% from the previous quarter

Key stats

What are the main financial stats of FOLD
Market
Shares outstanding
260.59M
Market cap
$3.2B
Enterprise value
$3.43B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
9.92
Price to sales (P/S)
12.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.97
Earnings
Revenue
$245.61M
EBIT
-$272.63M
EBITDA
-$264.82M
Free cash flow
-$254.39M
Per share
EPS
-$1.15
Free cash flow per share
-$0.98
Book value per share
$1.24
Revenue per share
$0.95
TBVPS
$2.71
Balance sheet
Total assets
$900.54M
Total liabilities
$580.27M
Debt
$440.58M
Equity
$320.27M
Working capital
$473.55M
Liquidity
Debt to equity
1.38
Current ratio
5.24
Quick ratio
4.96
Net debt/EBITDA
-0.87
Margins
EBITDA margin
-107.8%
Gross margin
88.4%
Net margin
-120.2%
Operating margin
-109.1%
Efficiency
Return on assets
-37%
Return on equity
-75.7%
Return on invested capital
-45.8%
Return on capital employed
-34.6%
Return on sales
-111%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FOLD stock price

How has the Amicus Therapeutics stock price performed over time
Intraday
3.02%
1 week
0.49%
1 month
-37.89%
1 year
24.67%
YTD
-46.82%
QTD
-46.82%

Financial performance

How have Amicus Therapeutics's revenue and profit performed over time
Revenue
$245.61M
Gross profit
$217.04M
Operating income
-$267.86M
Net income
-$295.18M
Gross margin
88.4%
Net margin
-120.2%
Amicus Therapeutics's gross profit has surged by 55% YoY and by 8% QoQ
FOLD's revenue has surged by 54% year-on-year and by 8% since the previous quarter
FOLD's net margin is up by 44% year-on-year and by 7% since the previous quarter
The operating margin rose by 38% YoY and by 9% QoQ

Growth

What is Amicus Therapeutics's growth rate over time

Valuation

What is Amicus Therapeutics stock price valuation
P/E
N/A
P/B
9.92
P/S
12.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.97
The EPS has grown by 27% YoY
The P/B is 84% above the 5-year quarterly average of 5.4 and 20% above the last 4 quarters average of 8.3
The equity has contracted by 42% YoY and by 11% from the previous quarter
FOLD's price to sales (P/S) is 82% lower than its 5-year quarterly average of 73.5 and 8% lower than its last 4 quarters average of 14.1
FOLD's revenue has surged by 54% year-on-year and by 8% since the previous quarter

Efficiency

How efficient is Amicus Therapeutics business performance
The ROS has grown by 45% YoY and by 8% from the previous quarter
Amicus Therapeutics's return on equity has decreased by 16% QoQ and by 7% YoY
FOLD's ROA is up by 10% YoY
The ROIC has grown by 9% from the previous quarter and by 7% YoY

Dividends

What is FOLD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FOLD.

Financial health

How did Amicus Therapeutics financials performed over time
FOLD's total assets is 55% greater than its total liabilities
The total liabilities has soared by 74% YoY and by 70% QoQ
Amicus Therapeutics's quick ratio has soared by 52% from the previous quarter but it has decreased by 16% YoY
FOLD's debt is 38% greater than its equity
FOLD's debt has surged by 118% since the previous quarter and by 115% year-on-year
The equity has contracted by 42% YoY and by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.